Finally, the status of the ferroptosis pathway was found to be significantly correlated with the clinical outcome and intratumoral heterogeneity of BC, and the expression of NDUFA13 was identified as a positive biomarker of ferroptosis pathway activation in patients with BC.31 Here, NDUFA13 is linked to breast cancer.